Archive by Author

Guest column on India & drug patents: Can the US force policy change?

19 Mar

The pharma giant Pfizer wants the US government to act more aggressively to defend the interests of the research-based pharmaceutical sector in India. Will it succeed?

The path from lobbying in Washington, D.C, to a change of policy in India is a long and uncertain one involving multiple steps. First, Pfizer needs to convince Congress that action against India is warranted. Second, Congress needs to get the United States Trade Representative (USTR) to apply pressures on the Indian government. And third, the pressures would need to be effective. In this post, I discuss the third link in the chain. Continue reading

%d bloggers like this: